| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | ANHU |
| Entrez GeneID | 183 |
| clone | 1B1 |
| WB Predicted band size | 53kDa |
| Host/Isotype | Mouse IgG2b |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human AGT expressed in E. Coli. |
| Formulation | Ascitic fluid containing 0.03% sodium azide. |
+ +
以下是关于AGT(血管紧张素原)抗体的3篇示例参考文献(注：文献信息为虚构示例，仅供格式参考，实际引用请核实真实来源)：
1. **文献名称**: *Development of a High-Specificity ELISA for Human Angiotensinogen Detection Using Monoclonal Antibodies*
**作者**: Tanaka K, et al.
**摘要**: 研究报道了一种基于单克隆抗体的高灵敏度ELISA检测方法，用于定量人血浆中的AGT水平，验证其在高血压患者中的临床应用价值。
2. **文献名称**: *Anti-AGT Autoantibodies in Preeclampsia: Pathogenic Role and Diagnostic Potential*
**作者**: Smith JL, et al.
**摘要**: 探讨了子痫前期患者体内存在的抗AGT自身抗体，发现其可能通过干扰肾素-血管紧张素系统加剧血管功能障碍，提示其作为生物标志物的潜力。
3. **文献名称**: *Therapeutic Targeting of Angiotensinogen with Neutralizing Antibodies in a Hypertensive Rat Model*
**作者**: Gupta R, et al.
**摘要**: 利用中和性抗AGT抗体在高血压大鼠模型中实现血压显著下降，证实了AGT抗体在心血管疾病治疗中的潜在干预作用。
如需真实文献，建议通过PubMed或Google Scholar以关键词“angiotensinogen antibody”检索，并筛选近年的实验研究论文。
Antibodies targeting angiotensinogen (AGT), a key component of the renin-angiotensin-aldosterone system (RAAS), have gained attention in cardiovascular and renal research. AGT, a liver-derived glycoprotein, serves as the precursor for angiotensin I, which is cleaved by renin to initiate the RAAS cascade. This system regulates blood pressure, fluid balance, and electrolyte homeostasis. Dysregulation of AGT or RAAS is implicated in hypertension, heart failure, chronic kidney disease, and preeclampsia.
AGT-specific antibodies are primarily used to study RAAS dynamics, quantify AGT levels in tissues or biofluids, and explore therapeutic interventions. Recent studies highlight their potential in blocking AGT production or activity to modulate RAAS overactivation, offering a novel approach for conditions like resistant hypertension. Monoclonal anti-AGT antibodies, in particular, are being investigated for their ability to selectively inhibit AGT without interfering with other RAAS components. Additionally, these antibodies aid in elucidating tissue-specific AGT roles, such as its local synthesis in adipose tissue or the brain. Challenges remain in optimizing antibody specificity across species and isoforms, given AGT's structural variations in humans and animal models. Ongoing research continues to refine AGT-targeting strategies for both diagnostic and therapeutic applications.
×
